Valuation: Repare Therapeutics Inc.

Market Cap 112M 97.97M 90.6M 83.14M 157M 10.8B 160M 1.08B 424M 5.27B 421M 412M 18.21B P/E 2023
-3.28x
P/E 2024 -0.66x
Enterprise Value -38.78M -33.89M -31.35M -28.76M -54.44M -3.74B -55.38M -374M -147M -1.82B -146M -142M -6.3B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
6 months+3.11%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.48
Extreme 1.48
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
35.75
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 28/01/2026
Director TitleAgeSince
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap.
28/01/26
BVF Partners LP
TenderCompany 10,166,943 23.5846%
28/01/26 Issuer sale

Controller/Auditor

82,122 0.1905%
28/01/26 Issuer sale

Chief Executive Officer

1,167,586 2.7085%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+85.31%-75.64% 114M
-1.07%+0.38%+2.06%+5.66% 50.35B
-2.85%-6.25%+366.61%+573.36% 39.21B
+1.78%+0.73%+32.68%-4.91% 34.52B
+1.98%+4.82%+13.71%+60.39% 34.6B
+0.06%-0.57%+3.35%+27.42% 27.05B
-3.27%-5.67% - - 16.68B
+1.64%+0.45%+70.86%+117.46% 15.11B
+0.29%+3.64%+15.30%+17.80% 13.85B
-1.21%+0.73%+18.02%-30.62% 13.18B
Average -0.31%+0.73%+67.55%+76.77% 24.47B
Weighted average by Cap. -0.53%+0.70%+77.65%+118.59%

Financials

2023 2024
Net sales 51.13 44.7 41.33 37.93 71.79 4.93K 73.03 492.95 193.65 2.41K 192.02 187.81 8.31K 53.48 46.74 43.23 39.67 75.08 5.15K 76.38 515.54 202.52 2.52K 200.83 196.42 8.69K
Net income -93.8M -81.99M -75.82M -69.58M -132M -9.04B -134M -904M -355M -4.41B -352M -345M -15.24B -84.69M -74.03M -68.46M -62.82M -119M -8.16B -121M -816M -321M -3.99B -318M -311M -13.76B
Net Debt -220M -192M -178M -163M -309M -21.22B -315M -2.12B -834M -10.36B -827M -809M -35.78B -151M -132M -122M -112M -212M -14.54B -215M -1.45B -571M -7.1B -567M -554M -24.51B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock